Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
21.55
-0.45 (-2.07%)
At close: May 22, 2026, 4:00 PM EDT
21.59
+0.04 (0.21%)
After-hours: May 22, 2026, 4:10 PM EDT
Forte Biosciences Employees
Forte Biosciences had 19 employees as of December 31, 2025. The number of employees increased by 5 or 35.71% compared to the previous year.
Employees
19
Change
5
Growth
35.71%
Revenue / Employee
n/a
Profits / Employee
-$3,992,368
Market Cap
527.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 19 | 5 | 35.71% |
| Sep 30, 2025 | 16 | 5 | 45.45% |
| Jun 30, 2025 | 17 | 6 | 54.55% |
| Mar 31, 2025 | 14 | 3 | 27.27% |
| Dec 31, 2024 | 14 | 5 | 55.56% |
| Sep 30, 2024 | 11 | 2 | 22.22% |
| Jun 30, 2024 | 11 | 4 | 57.14% |
| Mar 31, 2024 | 11 | 4 | 57.14% |
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Sep 30, 2023 | 9 | 3 | 50.00% |
| Jun 30, 2023 | 7 | 1 | 16.67% |
| Mar 31, 2023 | 7 | 2 | 40.00% |
| Dec 31, 2022 | 6 | 1 | 20.00% |
| Sep 30, 2022 | 6 | -4 | -40.00% |
| Jun 30, 2022 | 6 | -4 | -40.00% |
| Mar 31, 2022 | 5 | -4 | -44.44% |
| Dec 31, 2021 | 5 | -4 | -44.44% |
| Jun 30, 2021 | 10 | 5 | 100.00% |
| Mar 31, 2021 | 9 | 8 | 800.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| ProKidney | 231 |
| Prime Medicine | 146 |
| Sutro Biopharma | 137 |
| Kyverna Therapeutics | 130 |
| Prothena Corporation | 67 |
| Contineum Therapeutics | 51 |
| Climb Bio | 29 |
FBRX News
- 12 days ago - Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Business Wire
- 12 days ago - Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16) - TheFly
- 12 days ago - Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update - Business Wire
- 12 days ago - Forte Biosciences Quarterly report: Q1 2026 - Filings
- 12 days ago - Forte Biosciences Earnings release: Q1 2026 - Filings
- 24 days ago - Forte Biosciences Proxy statement: Proxy filing - Filings
- 6 weeks ago - Forte Biosciences 5.71M share Spot Secondary priced at $26.27 - TheFly
- 6 weeks ago - Forte Biosciences Announces Pricing of $150 Million Public Offering - Business Wire